Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
R&D Licensing
Filter     Order     Display # 
Date Item Title Hits
15 Mar 2010 AXIRON NDA currently under review by U.S. FDA for the treatment of testosterone deficiency in men 7
15 Mar 2010 Innate Immune, Inc. Enters into a License and Commercialization Agreement with Cephalon Australia Pty Ltd 18
12 Mar 2010 ˙Ipsen Grants Rhythm Exclusive Worldwide License 46
11 Mar 2010 AstraZeneca Extends Branded Generics Capability With Torrent Agreement 6
11 Mar 2010 Medivir outlicenses MIV-210 to Daewoong Pharmaceutical Co. Ltd. for clinical development 6
10 Mar 2010 TRANSGENE SIGNS AN EXCLUSIVE OPTION AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALISATION OF ITS IMMUNOTHERAPY PRODUCT TG4010 7
09 Mar 2010 Omeros Licenses PDE7 Compounds for Parkinson's Disease Program 8
08 Mar 2010 Acetylon Licenses Powerful Discovery Methodology and Platform from Harvard University and the Dana-Farber Cancer Institute for Development of Further Next-Generation Class II-Selective HDAC Inhibitor Compounds 67
03 Mar 2010 NicOx and Bausch + Lomb Announce Worldwide Licensing Agreement for NCX 116 10
03 Mar 2010 Transition Therapeutics Announces Licensing and Collaboration Agreement With Lilly 8
03 Mar 2010 Bristol-Myers Squibb and Allergan Enter Global Agreement on Investigational Neuropathic Pain Medicine 150
02 Mar 2010 SHIONOGI ENTERS INTO EXCLUSIVE LICENSE AGREEMENT WITH QUATRX PHARMACEUTICALS TO MARKET OSPEMIFENE 8
25 Feb 2010 Adamis Pharmaceuticals Signs Agreement to Acquire Prostate Cancer Drug Candidates 62
25 Feb 2010 Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 107
24 Feb 2010 Entered into Global Partnership with Basilea for an Azole Antifungual Agent Isavuconazole 128
18 Feb 2010 Biogen Idec and Swedish Orphan Biovitrum Update Hemophilia Partnership Agreement 63
16 Feb 2010 AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA) 70
15 Feb 2010 Meda in-licenses exclusive rights to Xerese 98
09 Feb 2010 Novartis gains exclusive rights to Debio 025, an antiviral agent in Phase IIb development as potential first-in-class hepatitis C therapy 14
08 Feb 2010 Sunesis Grants Carmot Therapeutics License to Its Drug Discovery Technology 153
08 Feb 2010 Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions 131
08 Feb 2010 Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche 148
08 Feb 2010 3SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 130
04 Feb 2010 Cannasat Announces Signing of Letter of Intent for In-Licensing of Parkinson's Disease Technology 50
04 Feb 2010 Lung Rx LLC, A Subsidiary Of United Therapeutics Corporation, And mondoBIOTECH holding AG Announce Today a Global Strategic Partnership Agreement for the Development Of Aviptadil Platform 29
04 Feb 2010 TenX Biopharma Licenses Zanolimumab From Genmab 17
03 Feb 2010 APEIRON AND GSK SIGN AN EXCLUSIVE LICENSE AGREEMENT FOR APEIRON'S THERAPEUTIC ENZYME PROJECT APN01 192
02 Feb 2010 Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 41
02 Feb 2010 Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial 19
01 Feb 2010 Starpharma and Lilly Sign New Drug Delivery Collaboration for Human Pharmaceuticals 232
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 1096

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

Oncology Market Leaders
Order Now

Subscribe La Merie Biologics